casimersen: Clinical Trials

5 trials of casimersen, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 enrolling by invitation, 1 terminated. 2 Phase 3, 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 32Completed 1, Terminated 1
Phase 11Completed 1
Phase 21Completed 1

Follow casimersen: new trials by email Literature Review of casimersen trials Research Report on casimersen

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.
Amondys 45, Exondys 51, Vyondys 53 - Duchenne Muscular Dystrophy
Phase 2CompletedKevin Flanigan32020-02-182023-10-26
A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice
Eteplirsen, Golodirsen, Casimersen - Duchenne Muscular Dystrophy
Enrolling by invitationSarepta Therapeutics, Inc.3002019-01-072025-09-10
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
Casimersen, Golodirsen - Duchenne Muscular Dystrophy
Phase 3TerminatedSarepta Therapeutics, Inc.1712018-08-022024-09-19
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)
SRP-4045, SRP-4053, Placebo - Duchenne Muscular Dystrophy
Phase 3CompletedSarepta Therapeutics, Inc.2282016-09-282025-11-18
Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
SRP-4045, Placebo - Duchenne Muscular Dystrophy
Phase 1CompletedSarepta Therapeutics, Inc.122015-10-082021-05-17

Conditions studied

Muscular Dystrophy, Duchenne (5)

Sponsors

Sarepta Therapeutics, Inc. (4)  ·  Kevin Flanigan (1)

Countries

United States (5)  ·  Belgium (2)  ·  Bulgaria (2)  ·  Canada (2)  ·  Czechia (2)  ·  France (2)  ·  Germany (2)  ·  Israel (2)  ·  Italy (2)  ·  Poland (2)  ·  Spain (2)  ·  Sweden (2)  ·  United Kingdom (2)  ·  Argentina (1)  ·  Australia (1)

Top investigators

Kevin Flanigan, MD (1)

Results publications

PMID 34105177, PMID 40098309, PMID 41961051

NIH funding

2015 (1), 2017 (1)